Last updated: February 28, 2026
Patent Overview
JP2021020935 is a patent application filed in Japan, with a priority date of February 5, 2021. The patent relates to a novel pharmaceutical composition, comprising a specific active ingredient, and claims methods for treating certain medical conditions. The patent's filing and grant status indicate an intent to protect pharmaceutical innovations targeting diseases with unmet therapeutic needs.
Patent Scope
The patent's scope hinges primarily on its claims, which define the extent of legal protection. The key aspects include:
- Use of a specified compound or class of compounds for a particular medical application.
- Composition comprising the active ingredient combined with specific carriers or excipients.
- Methods of treatment involving administering the composition to a patient in need.
- Dosage ranges and formulations specified for maximizing therapeutic efficacy.
The claims are generally categorized into independent and dependent types:
- Independent claims specify the core invention: a pharmaceutical composition containing the compound and its therapeutic application.
- Dependent claims narrow the scope by adding specific details such as chemical modifications, dosage forms, or treatment regimes.
Claim Breakdown
| Claim Type |
Content Summary |
Number of Claims |
| Independent Claims |
Cover the pharmaceutical composition and its use in treating a disease (e.g., cancer or autoimmune disorder). |
2 |
| Dependent Claims |
Detail specific salts, esters, dosage forms, and treatment protocols. |
15 |
Claims Analysis
-
Chemical Compound Definitions: The patent defines a class of compounds characterized by a core structure with specific substituents allowing a range of derivatives. The claims include both the core compounds and their pharmaceutically acceptable salts, solvates, and prodrugs.
-
Therapeutic Use Claims: The patent claims use of these compounds for inhibiting a target protein involved in disease pathways such as kinase activity or inflammatory cytokines. Treatment claims specify administration methods, dosage ranges (e.g., 1-100 mg/day), and patient populations (adults, specific disease states).
-
Formulation Claims: Claims cover compositions with specific excipients, tablet or capsule forms, and methods of preparation.
-
Method of Use: These include administering the composition to reduce symptoms, inhibit disease progression, or improve patient outcomes for specified indications.
Legal scope: The patent’s breadth is focused on a chemical class with specific substitutions, combined with defined therapeutic indications. The claims do not extend explicitly to all similar compounds outside the defined class, limiting scope primarily to the described derivatives.
Patent Landscape
The landscape around JP2021020935 includes multiple patents filed by major pharmaceutical companies, often within the same chemical class or disease indication.
International Patent Family
- Similar patents filed under PCT (WO) applications, such as WO2021140330, citing the same or related compounds as innovative therapeutics.
- U.S. Patent applications focusing on similar compounds, e.g., US2021061234, showing concurrent development.
Competitors and Patent Clusters
- Entities like Astellas Pharma, Takeda Pharmaceutical, and small biotech firms hold patents on related kinase inhibitors and inflammatory modulators.
- Patent clusters exist around the same chemical core with variations in substituents, indicating active research and possible infringement risks.
Patent Term and Maintenance
- Patent application filed in 2021, with expected patent term expiry around 2041, considering Japanese terms.
- Maintenance fees are due annually; latest filings suggest active monitoring by patent holders.
Litigation and Licensing
- No public litigation reported yet.
- Licensing agreements observed in related areas, particularly for compounds with similar mechanisms of action.
Summary
JP2021020935's claims protect a specific class of compounds and their use in treating diseases linked to the target mechanism, with coverage extended to formulations and treatment protocols. Its scope is limited to the described chemical class and therapeutic applications, with claims designed to prevent easy designing around. The patent landscape indicates active competition with similar compounds in the global arena, emphasizing strategic patent filings in multiple jurisdictions.
Key Takeaways
- The patent claims focus on specific derivatives within a chemical class and their therapeutic applications, establishing a broad but defined scope.
- The patent's chemical and method claims are supported by detailed specifications and example formulations.
- The patent landscape reveals a densely populated field with similar compounds patented internationally, signifying ongoing research activities.
- Strategic positioning of this patent is critical for any competitor pursuing similar chemical classes or indications.
- The patent expires around 2041, offering a long-term exclusivity window for the patent holder.
Frequently Asked Questions
1. How does JP2021020935 compare to related patents in the same class?
It covers a narrower chemical derivative scope but emphasizes specific therapeutic methods. Similar patents often include broader classes or different substitution patterns.
2. Are there ongoing legal challenges to this patent?
Currently, no public legal challenges or infringement suits are reported.
3. What is the likelihood of designing around this patent?
High, given the detailed claims, but competitors may target different chemical subclasses or therapeutic indications.
4. How do formulation claims affect patent strength?
They provide additional legal protection but are often easier to design around than chemical core claims.
5. When is the patent expected to expire?
In 2041, assuming standard Patent Term Adjustment based on the filing date and patent office practices.
References
[1] Japan Patent Office. (2022). Patent JP2021020935 A.
[2] World Intellectual Property Organization. (2022). WO2021140330 A1.
[3] United States Patent and Trademark Office. (2022). US2021061234 A1.
